ImmuPharma PLC
IMM
Company Profile
Business description
ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.
Contact
One Bartholomew Close
LondonEC1A 7BL
GBRT: +44 2072062650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.80 | 67.50 | 0.77% |
| CAC 40 | 8,263.15 | 63.86 | 0.78% |
| DAX 40 | 24,731.05 | 114.83 | 0.47% |
| Dow JONES (US) | 50,786.01 | 80.77 | -0.16% |
| FTSE 100 | 10,350.34 | 22.86 | -0.22% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 25,929.66 | 220.23 | 0.86% |
| Nikkei 225 | 65,416.63 | 1,392.03 | 2.17% |
| NZX 50 Index | 13,204.08 | 165.84 | 1.27% |
| S&P 500 | 7,405.73 | 21.99 | 0.30% |
| S&P/ASX 200 | 8,604.20 | 70.70 | 0.83% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |